ACRO Biomedical Secures Taiwanese Approval for Novel Collagen Ophthalmic Matrix to Address Global Corneal Transplant Shortage
• Taiwan's ACRO Biomedical has received regulatory approval from Taiwan's Ministry of Health and Welfare for its ABCcolla® Collagen Ophthalmic Matrix, offering a breakthrough solution for corneal transplantation.
• The product utilizes proprietary supercritical carbon dioxide decellularization technology to process porcine corneas into biocompatible alternatives to human donor tissue, potentially addressing the severe global shortage where only 100,000 of 20 million patients receive transplants annually.
• With patents in 15 countries and proven efficacy for corneal damage from trauma, infections, and melting, the technology positions ACRO Biomedical to capitalize on a market expected to grow from $500 million in 2024 to $1 billion by 2033.
© Copyright 2025. All Rights Reserved by MedPath